Marinol — Competitive Intelligence Brief

Marinol (DRONABINOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid [EPC]. Area: Metabolic.

marketed Cannabinoid [EPC] Cannabinoid receptors Metabolic Small molecule

Target snapshot

Marinol (DRONABINOL) — Wellhouse Pharma. Dronabinol acts on cannabinoid receptors in the CNS, potentially through central sympathomimetic activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Marinol TARGET	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone Oral Capsule	Nabilone Oral Capsule	Centre for Addiction and Mental Health	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Nabilone, flexible dosing	Nabilone, flexible dosing	University of Calgary	phase 3	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
ultra-micronized palmitoylethanolamide	ultra-micronized palmitoylethanolamide	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Endocannabinoid-like lipid mediator / PPAR-α agonist	PPAR-α; mast cell stabilization
Cannabidiol Oral Product	Cannabidiol Oral Product	University of Connecticut	marketed	Cannabinoid	Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid [EPC] class)

1. Bausch Health · 1 drug in this class
2. Wellhouse Pharma · 1 drug in this class